New drug AMT-253 enters human trials for Tough-to-Treat cancers

NCT ID NCT06209580

Recruiting now Disease control Sponsor: Multitude Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing an experimental drug called AMT-253 in about 96 people with advanced melanoma or other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then expanding to see how well the drug works. The main goals are to check safety and measure tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AMT-253 (an experimental drug given by IV)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced melanoma or other solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early, small study (96 people) focused mainly on safety and dosing. The drug may not shrink tumors or could cause serious side effects. Success in early phases does not guarantee later approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS MALIGNANT MELANOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.